keyword
MENU ▼
Read by QxMD icon Read
search

Olmesartan

keyword
https://www.readbyqxmd.com/read/28079608/mortality-and-differential-diagnoses-of-villous-atrophy-without-coeliac-antibodies
#1
Annalisa Schiepatti, Federico Biagi, Giacomo Fraternale, Claudia Vattiato, Davide Balduzzi, Simona Agazzi, Claudia Alpini, Catherine Klersy, Gino R Corazza
OBJECTIVE: Villous atrophy (VA) of the small bowel is mainly related to coeliac disease (CD), whose diagnosis is made on the basis of positive endomysial/tissue transglutaminase antibodies while on a gluten-containing diet in the vast majority of patients. However, VA can also occur in other conditions whose epidemiology is little known. Our aim was to study the epidemiology and clinical features of these rare enteropathies. PATIENTS AND METHODS: Clinical and laboratory data of all the patients with VA directly diagnosed in our centre in the last 15 years were collected and statistically analysed...
January 11, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28079534/practical-efficacy-of-olmesartan-versus-azilsartan-in-patients-with-hypertension-a-multicenter-randomized-controlled-trial-muscat-4-study
#2
Yuki Kakio, Haruhito A Uchida, Ryoko Umebayashi, Hidemi Takeuchi, Yuka Okuyama, Yoshihisa Hanayama, Jun Wada
BACKGROUND: Olmesartan and azilsartan, angiotensin II receptor blockers (ARBs), are expected to decrease blood pressure more than the other ARBs. We conducted randomized-controlled trials to compare the practical efficacy of olmesartan with azilsartan. METHODS: Eighty-four patients treated with the conventional ARBs for more than 3 months were assigned randomly to receive either 20 mg of olmesartan (olmesartan medoxomil, OL group) or 20 mg of azilsartan (azilsartan, not azilsartan medoxomil, AZ group) once daily for 16 weeks...
January 10, 2017: Blood Pressure Monitoring
https://www.readbyqxmd.com/read/28042253/small-bowel-enteropathy-associated-with-olmesartan-medoxomil-treatment
#3
Michail Galanopoulos, Lazaros Varytimiadis, Athanasios Tsigaridas, Pantelis S Karatzas, Emmanuel Archavlis, Nikos Viazis, Christina Vourlakou, Gerassimos J Mantzaris
Sprue-like enteropathy associated with treatment with olmesartan medoxomil, an angiotensin II receptor blocker, has been described recently. Herein, we report two patients who developed chronic severe non-bloody diarrhea, weight loss, and muscle wasting after prolonged use of olmesartan. Histologic and immunohistochemical examination of multiple duodenal biopsies revealed severe villous atrophy. Clinical signs ceased upon drug discontinuation. Physicians should be aware of this enteropathy even if olmesartan has been taken for months or years...
2017: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/28027072/spectrum-of-drug-induced-chronic-diarrhea
#4
Nissy A Philip, Nazir Ahmed, Capecomorin S Pitchumoni
The evaluation of a patient with chronic diarrhea can be quite frustrating, as it is expensive and involves multiple diagnostic studies. Moreover, identification of a drug as a cause of chronic diarrhea is a challenge in patients taking multiple medications. The disease may either be associated with intestinal mucosal changes, mimicking diseases such as celiac disease, or purely functional, with no histopathologic change. Drug-induced diarrhea may or may not be associated with malabsorption of nutrients, and a clinical improvement may occur within days of discontinuation of the drug, or may take longer when associated with mucosal injury...
February 2017: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/28005442/solid-lipid-nanoparticles-as-vesicles-for-oral-delivery-of-olmesartan-medoxomil-formulation-optimization-and-in-vivo-evaluation
#5
Mounika Nooli, Chella Naveen, Hitesh Kulhari, Nalini R Shastri, Ramakrishna Sistla
OBJECTIVE: Olmesartan medoxomil (OLM) is an antihypertensive drug with low oral bioavailability (28%) resulting from poor aqueous solubility, presystemic metabolism and P-glycoprotein (P-gp) mediated efflux. The present investigation studies the role of lipid nanocarriers in enhancing the OLM bioavailability through oral delivery. MATERIALS AND METHODS: Solid lipid nanoparticles were prepared by solvent emulsion-evaporation method. Statistical tools like regression analysis and Pareto charts were used to detect the important factors effecting the formulations...
December 22, 2016: Drug Development and Industrial Pharmacy
https://www.readbyqxmd.com/read/27972085/the-economic-value-of-olmesartan-for-the-treatment-of-hypertensive-patients-a-systematic-review
#6
F Gialama, G Kourlaba, G Gourzoulidis, K Tsioufis, N Maniadakis
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972007/the-clinical-value-of-olmesartan-for-the-treatment-of-hypertensive-patients-a-systematic-review
#7
G Kourlaba, F Gialama, K Vellopoulou, K Tsioufis, N Maniadakis
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27943353/two-selective-hptlc-methods-for-determination-of-some-angiotensin-ii-receptor-antagonists-in-tablets-and-biological-fluids
#8
Gamal A Salah, Hanaa M Abd El-Wadood, Mohamed Khairy, Ahmed A Khorshed
Two simple, selective, precise and highly sensitive high performance thin layer chromatographic (HPTLC) methods have been developed and validated for analysis of five angiotensin II receptor antagonists namely losartan, irbesartan valsartan, candesartan and olmesartan which widely used in clinical practice. High performance TLC of the drugs was performed on pre-coated silica gel HPTLC plates 60 F254 by development using mobile phase composed of chloroform: acetone: glacial acetic acid (7.8: 1.5: 0.7 v/v/v) which suitable for all of the studied drugs...
December 10, 2016: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/27916702/chronic-kidney-disease-accelerates-cognitive-impairment-in-a-mouse-model-of-alzheimer-s-disease-through-angiotensin-ii
#9
Takashi Nakagawa, Yu Hasegawa, Ken Uekawa, Shokei Kim-Mitsuyama
Epidemiological studies suggest that chronic kidney disease (CKD) is a significant risk factor in the development of cognitive decline. However, the exact role of CKD in cognitive impairment or dementia is unclear. This work was performed to examine the potential impact of CKD on cognitive impairment in Alzheimer's disease (AD), focusing on angiotensin II. (1) CKD was induced in 5XFAD mice, an AD model mouse, and wild-type mice by feeding an adenine-containing diet and the effect on cognitive function was compared between both strains...
January 2017: Experimental Gerontology
https://www.readbyqxmd.com/read/27907869/is-a-deuterated-internal-standard-appropriate-for-the-reliable-determination-of-olmesartan-in-human-plasma
#10
Edyta Piórkowska, Jacek Musijowski, Katarzyna Buś-Kwaśnik, Piotr J Rudzki
A right choice of the internal standard is one of the most challenging tasks during bioanalytical method development. Surprisingly, among the HPLC-MS methods for the determination of a cardiovascular drug olmesartan in plasma only structural analogues or similar compounds were used as internal standards. We have tried to answer the question whether the stable isotope labelled (deuterated) internal standard, as recommended by regulatory agencies, can be used for the reliable determination of olmesartan in human plasma...
January 1, 2017: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/27871084/olmesartan-prevents-microalbuminuria-in-db-db-diabetic-mice-through-inhibition-of-angiotensin-ii-p38-sirt1-induced-podocyte-apoptosis
#11
Junhui Gu, Ming Yang, Na Qi, Shuqin Mei, Jiejian Chen, Shuwei Song, Ying Jing, Meihan Chen, Liangliang He, Lijun Sun, Huimin Hu, Lin Li, Rudolf P Wüthrich, Ming Wu, Changlin Mei
BACKGROUND/AIMS: Blockage of the renin-angiotensin II system (RAS) prevents or delays albuminuria in diabetic patients. The aim of this study was to investigate the inhibitory mechanism of the angiotensin receptor blocker olmesartan on albuminuria in a murine model of diabetic nephropathy. METHODS: Male db/db diabetic mice were fed with placebo or 20 mg/kg olmesartan by daily gavage for 12 weeks. Conditionally immortalized mouse podocytes were treated with glucose, angiotensin II, olmesartan or p38 inhibitor s8307 in different experimental conditions after differentiation...
2016: Kidney & Blood Pressure Research
https://www.readbyqxmd.com/read/27822952/sprue-like-enteropathy-associated-with-olmesartan-in-a-patient-with-villous-atrophy-hla-dq2-genotype-and-antinuclear-antibodies
#12
Isidro Machado, María Reolid, Fernando Martínez de Juan, Carmen Martínez Lapiedra, Fernanda Maia de Alcántara
We describe a new case of enteropathy with villous atrophy in a patient suffering from arterial hypertension treated with olmesartan. The molecular and serological studies showed anti-nuclear antibodies (ANA) and haplotype HLA-DQ2 positive, as well as negative results for anti-transglutaminase, anti-endomysium and anti-enterocytes antibodies. A duodenal villous atrophy was suspected by upper gastrointestinal endoscopy, which was confirmed by histopathology. The morphological picture was suggestive of sprue-like enteropathy with severe lymphoid infiltration and predominant T lymphoid cells...
November 2016: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/27815174/comparative-biodistribution-and-safety-profiling-of-olmesartan-medoxomil-oil-in-water-oral-nanoemulsion
#13
Bapi Gorain, Hira Choudhury, Rakesh Kumar Tekade, Saumen Karan, P Jaisankar, Tapan Kumar Pal
Poor aqueous solubility and unfavourable de-esterification of olmesartan medoxomil (a selective angiotensin II receptor blocker), results in low oral bioavailability of less than 26%. Improvement of oral bioavailability with prolonged pharmacodynamics activity of olmesartan in Wistar rats had been approached by nanoemulsification strategy in our previous article [Colloid Surface B, 115, 2014: 286]. In continuation to that work, we herewith report the biodistribution behaviour and 28-day repeated dose sub-chronic toxicity of olmesartan medoxomil nanoemulsion in Wistar rats following oral administration...
December 2016: Regulatory Toxicology and Pharmacology: RTP
https://www.readbyqxmd.com/read/27803820/seronegative-intestinal-villous-atrophy-a-diagnostic-challenge
#14
Cláudio Martins, Cristina Teixeira, Suzane Ribeiro, Daniel Trabulo, Cláudia Cardoso, João Mangualde, Ricardo Freire, Ana Luísa Alves, Élia Gamito, Isabelle Cremers, Ana Paula Oliveira
Celiac disease is the most important cause of intestinal villous atrophy. Seronegative intestinal villous atrophy, including those that are nonresponsive to a gluten-free diet, is a diagnostic challenge. In these cases, before establishing the diagnosis of seronegative celiac disease, alternative etiologies of atrophic enteropathy should be considered. Recently, a new clinical entity responsible for seronegative villous atrophy was described-olmesartan-induced sprue-like enteropathy. Herein, we report two uncommon cases of atrophic enteropathy in patients with arterial hypertension under olmesartan, who presented with severe chronic diarrhea and significant involuntary weight loss...
2016: Case Reports in Gastrointestinal Medicine
https://www.readbyqxmd.com/read/27803450/olmesartan-prevented-intra-articular-inflammation-induced-by-zymosan-in-rats
#15
Gerlane Coelho Bernardo Guerra, Marília Stefani Souza de Menezes, Aurigena Antunes de Araújo, Raimundo Fernandes de Araújo Júnior, Caroline Addison Carvalho Xavier de Medeiros
The objective of this study was to study the effect of olmesartan medoxomil (OLM), an antihypertensive drug, on intra-articular inflammation induced by zymosan (Zy) in Wistar rats. Intra-articular inflammation was induced in the right knees of rats by 1 mg Zy dissolved in saline. The animals were divided into the following groups: saline only (oral saline and intra-articular saline); Zy only (intra-articular Zy and oral saline), and intra-articular Zy and oral OLM (5, 15, or 30 mg/kg) or diclofenac sodium (SD; 100 mg/kg)...
2016: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/27801805/urinary-angiotensinogen-could-be-a-prognostic-marker-of-the-renoprotection-of-olmesartan-in-metabolic-syndrome-patients
#16
Tomoko Mizushige, Hiroyuki Kobori, Hirofumi Hitomi, Yoko Nishijima, Fumihiro Tomoda, Satoshi Morimoto, Masakazu Kohno, Akira Nishiyama
This study was performed to demonstrate urinary angiotensinogen as a potential prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. In 24 patients (eight women, 57.88 ± 2.00 years), 5-40 mg/day of olmesartan were given. Urinary concentrations of albumin and angiotensinogen (normalized by urinary concentrations of creatinine) and plasma renin activity were measured before and after the 12- and 24-week marks of olmesartan treatment. Olmesartan treatment increased plasma renin activity and decreased urinary albumin and urinary angiotensinogen significantly (p < 0...
October 27, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27793937/effect-of-olmesartan-on-the-level-of-oral-cancer-risk-factor-pai1
#17
Stavros Vassiliou, Emeka Nkenke, Nikos Lefantzis, Anastasios Ioannidis, Christos Yapijakis, Margarita Zoga, Veronica Papakosta, Spyridoula Derka, Chryssoula Nikolaou, Eleftherios Vairaktaris
AIM: To study if the angiotensin receptor blocker olmesartan reduces levels of plasminogen activator inhibitor 1 (PAI1), a risk factor for oral cancer, in a mouse model and therefore whether it could be used in the treatment of this malignancy. MATERIALS AND METHODS: Twelve transgenic PAI1 mice aged 16-20 weeks were divided in two groups each containing six animals. One group was given olmesartan every day for 30 days in drinking water in an amount corresponding to their weight, 0...
2016: Anticancer Research
https://www.readbyqxmd.com/read/27788510/blood-pressure-reduction-is-associated-with-the-changes-in-oxidative-stress-and-endothelial-activation-in-hypertension-regardless-of-antihypertensive-therapy
#18
Martina Mihalj, Refmir Tadzic, Aleksandar Vcev, Silvija Rucevic, Ines Drenjancevic
BACKGROUND/AIMS: Hypertensive patients present with increased oxidative stress and frequently receive angiotensin II (ANGII) receptor type I blockers (ARB) for blood pressure (BP) reduction. Recent studies revealed an important role of ANGII in maintaining vascular oxidative homeostasis, including sustaining normal sodium dismutase activity. This study aimed to investigate the effects of antihypertensive therapy and also vitamin C/E supplementation on BP, oxidative stress and endothelial activation in patients with essential hypertension...
2016: Kidney & Blood Pressure Research
https://www.readbyqxmd.com/read/27754281/hw-04-1-usefulness-of-big-data-in-clinical-research
#19
Rae Woong Park
Big data indicates the large and ever-increasing volumes of data adhere to the following 4Vs: volume (ever-increasing amount), velocity (quickly generated), variety (many different types), veracity (from trustable sources). The last decade has seen huge advances in the amount of data we routinely generate and collect in pretty much everything we do, as well as our ability to use technology to analyze and understand it. The routine operation of modern health care systems also produces an abundance of electronically stored data on an ongoing basis as a byproduct of clinical practice...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27754167/sy-12-3-are-ras-inhibitors-necessary-for-all-patients-with-diabetes-and-chronic-kidney-disease
#20
Shokei Kim-Mitsuyama
There is accumulating evidence that RAS inhibitors not only reduce blood pressure, but also exert pleiotropic effects, including a renoprotective effect, amelioration of insulin resistance, reduction in onset of diabetes, and suppression of cardiovascular remodelling,. However, the definite benefit of RAS inhibition in treatment of hypertension with CKD or DM is not conclusive. We previously performed the OlmeSartan and Calcium Antagonists Randomized (OSCAR) study comparing the preventive effect of high-dose ARB therapy versus ARB plus CCB combination therapy on cardiovascular morbidity and mortality in 1164 Japanese elderly hypertensive patients with baseline type 2 diabetes and/or CVD (Am J Med (2012))...
September 2016: Journal of Hypertension
keyword
keyword
11664
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"